

Supplemental Tables

Clinical trials				
Tumor Type	Local study name	Dutch trial register number	EMC-METC	Number of included cartridges
Breast	248		MEC06-248	253
	405		MEC09-405	297
	CareMore – AI	NL4884	MEC14-588	92
	CareMore – Trastuzumab	NL4977	MEC14-589	39
	CTC-cDDP	NL3885	MEC13-007	55
	IMPACT		MEC16-313	159
	Liquor	NL5408	MEC15-419	75
Prostate	CABARESC	NL2849	MEC11-324	210
	Prelude		N.A.	41
	Process		MEC16-464	24
Colorectal	Miracle		MEC15-289	151
	RMD		MEC06-089	265
Bladder	CirGuidance	NL3954	MEC13-301	301

Supplemental Table 1. Trial details of included cartridges. For more information visit: <https://www.trialregister.nl/>

Origin cells	Cell type	Number of ACCEPT events
Breast cancer cell line	MCF-7	1616
	SKBR-3	530
	TD47D	1249
Prostate cancer cell line	LNCAP	1054
Patient derived leukocytes	Lymphocytes	130

Supplemental Table 2. ACCEPT results Reference data

		ACCEPT - Results		
		N Events (% of CellSearch® result)	N CK+ events (% of total ACCEPT result)	N CK+/DAPI+ events (% of total ACCEPT result)
Breast	Total	51022 (99%)	50795	44672
	Blood	45695 (94.3%)	45472 (99.5%)	39394 (86.2%)
	Liquor	5327 (162%)	5323 (99.9%)	5278 (99.1%)
Prostate		20624 (100.1%)	20100 (97.5%)	18421 (89.3%)
Colorectal		934 (149%)	519 (55.6%)	442 (47.3%)
Bladder		260 (100%)	198 (76.2%)	189 (72.69%)

Supplemental Table 3. Description of ACCEPT events in relation to CellSearch® data

		DAPI - Type of ACCEPT event					
		Material	Single CTC	Doublet	Small cluster	Large cluster	Total
Breast	Blood		33696	624	23	0	34343
	Liquor		4515	58	2	0	4575
Prostate	Blood		13127	224	5	0	13356
Colorectal	Blood		252	3	0	0	255
Bladder	Blood		93	4	2	0	99
Total			51683	913	32	0	52628

Supplemental Table 4. Nucleus singularity determination (in CK+, single CTC, DAPI+, DAPI<CK ACCEPT events)